C-Rad AB (publ) (CRAD-B.ST)
SEK 29.55
(0.34%)
SEK 29.55
(0.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 35.52 Million SEK | 375.05% |
| 2022 | 7.47 Million SEK | -70.21% |
| 2021 | 25.1 Million SEK | 74.74% |
| 2020 | 14.36 Million SEK | 204.09% |
| 2019 | -13.8 Million SEK | -165.12% |
| 2018 | 21.19 Million SEK | 294.29% |
| 2017 | -10.9 Million SEK | 65.05% |
| 2016 | -31.2 Million SEK | -47.33% |
| 2015 | -21.18 Million SEK | -236.33% |
| 2014 | -6.29 Million SEK | 70.0% |
| 2013 | -20.99 Million SEK | -8.28% |
| 2012 | -19.38 Million SEK | 54.49% |
| 2011 | -42.6 Million SEK | -333.07% |
| 2010 | -9.83 Million SEK | 4.02% |
| 2009 | -10.25 Million SEK | 4.4% |
| 2008 | -10.72 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 10.6 Million SEK | -33.75% |
| 2024 Q3 | 15.4 Million SEK | 45.28% |
| 2024 Q1 | 16 Million SEK | -39.62% |
| 2023 Q1 | 3.2 Million SEK | -28.56% |
| 2023 FY | 35.52 Million SEK | 375.05% |
| 2023 Q4 | 26.5 Million SEK | 143.12% |
| 2023 Q2 | 5.4 Million SEK | 68.75% |
| 2023 Q3 | 10.9 Million SEK | 101.85% |
| 2022 Q3 | 7.1 Million SEK | 344.83% |
| 2022 Q1 | -1.2 Million SEK | -110.52% |
| 2022 Q2 | -2.9 Million SEK | -141.67% |
| 2022 FY | 7.47 Million SEK | -70.21% |
| 2022 Q4 | 4.47 Million SEK | -36.92% |
| 2021 Q3 | 4.9 Million SEK | -12.5% |
| 2021 FY | 25.1 Million SEK | 74.74% |
| 2021 Q2 | 5.6 Million SEK | 75.0% |
| 2021 Q1 | 3.2 Million SEK | -74.53% |
| 2021 Q4 | 11.4 Million SEK | 132.69% |
| 2020 FY | 14.36 Million SEK | 204.09% |
| 2020 Q3 | 3.8 Million SEK | 258.33% |
| 2020 Q2 | -2.4 Million SEK | -700.0% |
| 2020 Q1 | 400 Thousand SEK | 103.23% |
| 2020 Q4 | 12.56 Million SEK | 230.66% |
| 2019 Q1 | 800 Thousand SEK | -96.71% |
| 2019 Q2 | -900 Thousand SEK | -212.5% |
| 2019 Q3 | -1.4 Million SEK | -55.56% |
| 2019 FY | -13.8 Million SEK | -165.12% |
| 2019 Q4 | -12.4 Million SEK | -785.71% |
| 2018 Q4 | 24.29 Million SEK | 7997.0% |
| 2018 Q2 | 1.6 Million SEK | 132.65% |
| 2018 FY | 21.19 Million SEK | 294.29% |
| 2018 Q1 | -4.9 Million SEK | -648.71% |
| 2018 Q3 | 300 Thousand SEK | -81.25% |
| 2017 Q3 | -1.7 Million SEK | 60.31% |
| 2017 Q1 | -5.84 Million SEK | -27.27% |
| 2017 FY | -10.9 Million SEK | 65.05% |
| 2017 Q4 | 893 Thousand SEK | 152.53% |
| 2017 Q2 | -4.28 Million SEK | 26.74% |
| 2016 Q3 | -7.97 Million SEK | 20.76% |
| 2016 Q4 | -4.59 Million SEK | 42.43% |
| 2016 FY | -31.2 Million SEK | -47.33% |
| 2016 Q1 | -8.56 Million SEK | -39.38% |
| 2016 Q2 | -10.06 Million SEK | -17.49% |
| 2015 Q1 | -1.79 Million SEK | 60.74% |
| 2015 FY | -21.18 Million SEK | -236.33% |
| 2015 Q4 | -6.14 Million SEK | 16.02% |
| 2015 Q3 | -7.32 Million SEK | -23.78% |
| 2015 Q2 | -5.91 Million SEK | -228.67% |
| 2014 Q1 | -1.9 Million SEK | 28.94% |
| 2014 Q3 | -2.59 Million SEK | -193.23% |
| 2014 FY | -6.29 Million SEK | 70.0% |
| 2014 Q4 | -4.58 Million SEK | -76.41% |
| 2014 Q2 | 2.78 Million SEK | 246.41% |
| 2013 FY | -20.99 Million SEK | -8.28% |
| 2013 Q1 | -5.91 Million SEK | -304.95% |
| 2013 Q2 | -10.33 Million SEK | -74.61% |
| 2013 Q3 | -2.06 Million SEK | 80.06% |
| 2013 Q4 | -2.67 Million SEK | -29.97% |
| 2012 Q1 | -7.17 Million SEK | 71.22% |
| 2012 FY | -19.38 Million SEK | 54.49% |
| 2012 Q4 | -1.46 Million SEK | 72.04% |
| 2012 Q3 | -5.22 Million SEK | 5.45% |
| 2012 Q2 | -5.52 Million SEK | 22.92% |
| 2011 Q1 | -5.15 Million SEK | -60.15% |
| 2011 Q4 | -24.92 Million SEK | -532.2% |
| 2011 Q2 | -8.58 Million SEK | -66.49% |
| 2011 Q3 | -3.94 Million SEK | 54.09% |
| 2011 FY | -42.6 Million SEK | -333.07% |
| 2010 Q2 | -4.3 Million SEK | -167.54% |
| 2010 Q3 | -710 Thousand SEK | 83.5% |
| 2010 Q1 | -1.6 Million SEK | -37.96% |
| 2010 FY | -9.83 Million SEK | 4.02% |
| 2010 Q4 | -3.22 Million SEK | -353.54% |
| 2009 Q3 | -3.61 Million SEK | -24.53% |
| 2009 Q2 | -2.9 Million SEK | -12.96% |
| 2009 Q1 | -2.56 Million SEK | 33.78% |
| 2009 FY | -10.25 Million SEK | 4.4% |
| 2009 Q4 | -1.16 Million SEK | 67.75% |
| 2008 FY | -10.72 Million SEK | 0.0% |
| 2008 Q2 | -1.47 Million SEK | 42.93% |
| 2008 Q1 | -2.59 Million SEK | 0.0% |
| 2008 Q3 | -2.61 Million SEK | -77.2% |
| 2008 Q4 | -3.87 Million SEK | -48.14% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 145.644% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 65.672% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 65.672% |
| Arcoma AB | 2.56 Million SEK | -1285.686% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 125.675% |
| BICO Group AB (publ) | -835.7 Million SEK | 104.251% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | -42.247% |
| CellaVision AB (publ) | 130.3 Million SEK | 72.735% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 144.527% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 221.73% |
| Duearity AB (publ) | -26.19 Million SEK | 235.659% |
| Dignitana AB (publ) | -17.36 Million SEK | 304.625% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 137.478% |
| Getinge AB (publ) | 2.41 Billion SEK | 98.527% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 152.266% |
| Iconovo AB (publ) | -45.89 Million SEK | 177.416% |
| Integrum AB (publ) | 4.03 Million SEK | -781.071% |
| Luxbright AB (publ) | -25.37 Million SEK | 240.015% |
| Mentice AB (publ) | -2.81 Million SEK | 1361.235% |
| OssDsign AB (publ) | -130.49 Million SEK | 127.227% |
| Paxman AB (publ) | 8.33 Million SEK | -326.519% |
| Promimic AB (publ) | -9.22 Million SEK | 485.264% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 122.212% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 163.918% |
| ScandiDos AB (publ) | -14.64 Million SEK | 342.568% |
| Sectra AB (publ) | 428.38 Million SEK | 91.706% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 159.6% |
| Senzime AB (publ) | -134.14 Million SEK | 126.485% |
| SpectraCure AB (publ) | -20.44 Million SEK | 273.812% |
| Stille AB | 26.64 Million SEK | -33.337% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 100.923% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 61.306% |